Many jobs now require long hours for productivity and professional growth. Prolonged workdays harm cardiovascular health ...

A new study from researchers at Wake Forest University School of Medicine shows that only 3.5 years of intensive blood ...

Dr. Gilbert J. Zoghbi, MD. FACC, FSCAI discusses renal denervation therapy, a new FDA-approved treatment for resistant ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...

Women with persistent short sleep during the peripartum period had significantly increased odds of developing metabolic syndrome.

Preventing preeclampsia in chronic hypertension may reduce severe maternal morbidity to normotensive levels, new research ...

Ageing, lifestyle changes, limited healthcare, and socio-economic challenges contribute to rising mortality among Kenya's ...

Discover how cruciferous vegetables naturally combat high blood pressure through unique compounds that support heart health ...

The AHA’s Target BP initiative is a movement to increase blood pressure control among adults living with hypertension in the United States.

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...